CLINICAL_TRIALS ClinicalTrials.gov record update

Combination of Immune Checkpoint Inhibitors Tislelizumab and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Single-arm, Single-center, Phase 2 Clinical Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05310383
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:43.229861+00:00
Published At: 2022-04-11T00:00:00+00:00
Record Updated At: 2022-04-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Cervical Carcinoma", "Metastatic Cervical Carcinoma", "Persistent Cervical Carcinoma", "Radiotherapy", "Immunotherapy", "Anti-programmed Cell Death Receptor 1", "Immune Checkpoint Inhibitors", "Tislelizumab", "Objective Response Rate", "Survival Outcomes"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-04-11"
protocolSection.identificationModule.nctId: "NCT05310383"
protocolSection.identificationModule.officialTitle: "Combination of Immune Checkpoint Inhibitors Tislelizumab and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Single-arm, Single-center, Phase 2 Clinical Study"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.